TY - JOUR T1 - Persistent homology derived radiomic feature predicts survival in non-small cell lung cancer patients treated with SBRT JF - medRxiv DO - 10.1101/2022.06.21.22276718 SP - 2022.06.21.22276718 AU - Eashwar Somasundaram AU - Raoul R. Wadhwa AU - Adam Litzler AU - Rowan Barker-Clarke AU - Peng Qi AU - Gregory Videtic AU - Kevin Stephans AU - Nathan A. Pennell AU - Daniel Raymond AU - Kailin Yang AU - Michael W. Kattan AU - Jacob G. Scott Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/24/2022.06.21.22276718.abstract N2 - Introduction Predicting survival in NSCLC is a goal of clinicians in guiding therapy, trialists in risk stratifying patients, and patients for prognosis counseling. Traditional risk calculators for survival use clinical and histopathologic data to predict survival. We propose incorporating the PHOM (persistent homology) score, the radiomic quantification of solid tumor topology, to predict overall survival.Methods Patients diagnosed with stage I or II NSCLC and status post definitive SBRT treatment were selected (n = 554). The PHOM score was calculated on each patient’s pre-treatment CT scan. PHOM score, age, sex, stage, KPS, CCI, and post-SBRT chemotherapy were predictors in the generated Cox proportional hazards models for overall and cancer-specific survival. Patients were split into high and low PHOM score groups by median value and compared using KM curves for overall survival and cumulative incidence curves for cause specific death. Optimized tertile PHOM risk groups were calculated and similarly compared for overall survival and cause-specific death. Internal validation was conducted with bootstrap resampling and calibration curves were checked. Finally, a nomogram to predict overall survival was generated and is publicly available at https://eashwarsoma.shinyapps.io/LungCancerTDATest/.Results PHOM score was a significant predictor for overall survival (HR: 1.17, 95% CI: 1.07 −1.28) and was the only significant predictor for cancer-specific survival (1.31, 95% CI: 1.11−1.56) in the multivariable Cox model. The median survival for the high PHOM group was 29.18 months (95% CI: 23.62− 34.27), which was significantly worse compared to the low PHOM group (45.41 months, 95% CI: 40.08− 51.78, p < 0.001). The high PHOM group had a significantly greater chance of cancer-specific death at post treatment month 65 (0.244, 95%CI: 0.192−0.296) compared to the low PHOM group (0.171, 95% CI: 0.123−0.218, p = 0.029). Nomograms for 1, 2, 5, and 8-year overall survival were successfully calibrated using the Cox model.Conclusions The PHOM score is associated with cancer-specific survival and predictive of overall survival. Our developed nomogram can be used to inform clinical prognosis and assist in making post-SBRT treatment considerations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJGS was supported by NIH grant R37 CA244613 and American Cancer Society. ES and RRW were supported by the Case Comprehensive Cancer Center Summer Training Grant for medical students. KY was supported by the Computational Genomic Epidemiology of Cancer (CoGEC) Program at Case Comprehensive Cancer Center (T32CA094186), Young Investigator Award from ASCO Conquer Cancer Foundation, and RSNA Research Resident Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Cleveland Clinic Foundation gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://github.com/eashwarsoma/phom-lungca-ccf https://eashwarsoma.shinyapps.io/LungCancerTDATest/ ER -